laboratory. The growth medium consisted of Eagie's minimum essential medium (MEM) (13) with added fetal calf serum to a concentration of 2-5%. The serum had been inactivated at 56°C for 30 rain.
For virus titrations and determination of drug sensitivity of virus sometimes a continuous cell line derived from African green monkey kidney tissue (GMK) was used, kindly supplied by Dr. H. Lennartz, Hamburg, FRG. It was maintained in serial passages by growth in MEM with 10% fetal calf serum.
Infectivity Titrations. Virus titrations in tube cultures were essentially done as described before (8) . The maintenance medium for primary cultures was MEM, for GMK cell cultures MEM with 2% fetal calf serum. Concentration of infective virus was expressed in terms of 50% tissue culture infective doses (TCIDso) per 0.1 ml.
Plaque assays were performed on primary monkey kidney or GMK cell monolayers. After 1-h adsorption at room temperature the inoculum was removed and the plates overlaid with 5 ml of a mixture consisting of equal volumes of 1.8% agar and two times concentrated reinforced Eagle's MEM (14) with 2 or 5% fetal calf serum. Infectivity titers of unadapted echo 9 or Coxsackie A 9 virus in GMK cultures were usually 2-3 times lower than in primary cultures, but all titrations from the same experiment were clone simultaneously in the same Cell system. Drug Sensitivity Tests. They were done in tube cultures or by plaque technique as described previously (8, 15) .
Neutralization Tests. The technique followed a standard tube neutralization test which has been described in detail previously (16) . (11) as hydrochloride salt. It was kindly synthesized for us by Farbwerke Hoechst AG, Hoechst, FRG. Guanidine, as hydrochloride salt, was purchased from E. Merck, Darmstadt, FRG.
Compounds. HBB was used throughout in its D-(-) optical isomeric form
Mice. NMRI mice were either purchased from an animal supply house or reared in the Institute's animal quarters. Mice were infected, less than 24-h old, by subcutaneous inoculation of virus dilutions in 0.02 ml vol. The mice were observed for 21 days at least once a day, and clinical manifestations as well as deaths were recorded. Concentration of virus in mice was expressed in terms of 50% paralyzing doses (PDs0) per 0.02 ml.
Standard treatment of mice consisted of subcutaneous inoculations of 0.02 ml vol of saline (0.9% sodium hydrochloride in pyrogen-free water) with or without compounds as indicated, beginning at the time of virus inoculation and extending for usually 10 days. The inoculations were administered into the region of the forearm two times daily, with the right and left side alternating. The standard concentrations of compounds were 10 mM HBB plus 100 mM guanidine for combined treatment, for HBB alone 10 mM HBB, and for guanidine alone 100 mM guanidine.
As indicated in the text, isolation of more mouse-virulent echo virus 9 was achieved by passage in Swiss albino mice. These were kindly provided by ASTA-Werke AG, Brackwede, FRG.
Results

Protective Action of Combined Treatment against Echo Virus Type 9 Disease.
Litters of newborn mice were infected with 1-5 PDso of cell culture-grown echo virus 9, corresponding to about 2 × 106 plaque-forming units (PFU) per mouse. Starting at time of virus inoculation, they were simultaneously treated in 0.02 ml doses two times daily for 8-10 days by subcutaneous inoculations of 10 mM HBB plus 100 mM guanidine, by 10 mM HBB alone, or 100 mM guanidine alone, respectively. Assuming an initial body weight of a mouse of about 1 g and uniform distribution of compound, a final concentration of 200 ~M HBB and 2 mM guanidine might be achieved in the animal after one inoculation. These are well tolerated and highly virus-inhibitory concentrations of the compounds in cell culture (8) .
The results of 11 experiments extending over half a year are summarized in Table I . In the virus control group more than 90% of the animals became paralyzed and 85% of the paralyzed mice died. In some experiments, the mice of the control group were kept untreated; in most cases they were inoculated two times daily with saline, but this apparently did not influence the outcome of the experiment. The protective effect of the combined treatment with HBB plus guanidine is obvious: out of 111 mice only 4 became ill, and 3 of these 4 mice had only a slight muscular weakness of short duration. Even the fourth mouse probably would have survived, but, unfortunately, was eaten by its mother. On the other hand, HBB or guanidine treatment alone were ineffective.
That the protective effect of combined treatment is not limited to relatively low doses of virus is demonstrated in Table II . More virulent variants of virus were prepared by repeated virus passages in Swiss albino mice (10) . It can be seen that combined treatment with HBB plus guanidine, according to the schedule outlined above, protects completely against more than 103 PDs0. HBB alone, even in 20 mM concentration, had no demonstrable protective effect. The clinical success of treatment can be correlated with inhibition of virus multiplication as seen in the following experiment.
Inhibition of Virus Multiplication in Treated Mice. Groups of newborn mice were infected with five PD50 of echo virus 9 and treated two times daily for 91/2 days with either saline, 10 mM HBB plus 100 mM guanidine, 10 mM HBB alone, or 100 mM guanidine alone, respectively. At indicated times after virus inoculation, two mice of each group were collected and frozen at -20°C. Subsequently, of each mouse a 20% suspension in MEM was prepared and the virus content determined in rhesus monkey kidney cell cultures. In Fig. 1 the geometric means of the titrations are presented. Clearly, a significant inhibition of echo virus 9 multiplication was found in the group treated with HBB plus guanidine, though ultimately also in this group the virus titers reached high levels. However, as known from previous studies (10) , this delay in virus multiplication is quite sufficient to prevent echo virus 9 disease in mice. On the nature of the "breakthrough" virus, we shall comment below. It should be stressed that not in all experiments a late virus multiplication occurred in the treated group (see, e.g., Fig. 6 ). It is also obvious from this experiment that treatment with HBB or guanidine alone had no effect on virus multiplication which corresponds to the lack of clinical improvement under these two treatments.
Modifications of the Standard Schedule of Combined Treatment. Since echo virus 9 multiplication does reach its maximum in newborn mice around 3-4 days (10) (see also Figs. 1 and 6), an attempt was made to abbreviate the combined treatment with HBB plus guanidine. Groups of mice, after inoculation of five PDso of echo virus 9, were subjected to standard treatment, which, however, was cut short to only 5 or 3 days, respectively (Table III) . Not only 5 days but even 3 m ?.
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Multiplication of echo virus 9 in newborn mice, treated two times daily for 91/2 days with either saline, 10 mM HBB plus I00 mM guanidine, 10 mM HBB alone, or 100 mM guanidine alone, respectively. days of treatment beginning with virus inoculation were sufficient for prevention of paralysis. In a complementary experiment of similar design (five PDs0 per mouse), combined treatment was delayed for 24 or 48 h after virus inoculation, respectively (Table IV) . Postponement of treatment for even 48 h was sufficient for protection of the animals. The dose of drugs administered appeared to be critical (Table V) . When only half of the standard dose of combined treatment was inoculated (5 mM HBB plus 50 mM guanidine), no longer complete, though still significant, protection of mice inoculated with five PDso of echo virus 9 was achieved. Quarter doses (2.5 mM HBB plus 25 mM gnanidine) were ineffective. Results comparable to those with half of the standard dose were obtained when the standard dose of HBB plus guanidine was administered only once daily instead of twice per day (Table  VI) .
Toxicity of Treatment. Toxicity experiments were carried out by treating marked mice from single litters with saline or test substances in saline, respectively. Treatment was begun in animals less than 24-h old and maintained for 10-11 days. Inoculations were administered two times daily, 0.02 ml per mouse per injection. Weights of all mice were taken daily. Under these conditions 20 mM HBB or 100 mM guanidine, respectively, never proved toxic. In several experiments 200 mM guanidine led to cyanosis in the mice, and these animals frequently died or were eaten by their mothers. 20 mM HBB plus 200 mM guanidine injected together sometimes also proved toxic, in other experiments it was tolerated and no difference in weight gain to the saline control was detected (Fig. 2) . Whether HBB acts somewhat alleviating on gnanidine toxicity cannot be decided.
Drug Sensitivity of Virus Recovered from Treated Mice. HBB or guanidine treatment alone of echo virus 9-infected mice is ineffective (Table I) , and no inhibition of virus multiplication in the animals thus treated can be demonstrated (Fig. 1) . Since drug-resistant mutants can be easily obtained in cell culture, it has been argued that development of drug resistance might be the cause of clinical ineffectiveness. Therefore, echo virus 9 recovered at various times after infection from HBB-or guanidine-treated mice with clinical disease was tested for HBB or guanidine sensitivity and compared with material isolated from corresponding animals of the saline group as well as the virus originally inoculated.
Drug sensitivity was measured as described before (8) by recording the (no survivors) * 0.02 ml inoculated subcutaneously two times daily until 101/2 days postinoculation of virus. * Number of mice paralyzed over total number of mice. * 0.02 ml of saline or drugs inoculated subcutaneously two times daily for 10x/2 days, beginning at time of virus inoculation. * Number of mice paralyzed over total number of mice.
TABLE VI
Effect of Combined Treatment Given Only One Time Per Day
Saline* 10 mM HBB + 100 mM guanidine
Two times daily
One time daily 9/9* 0/9 4/9 (no survivors) (7 survivors) * 0.02 ml of saline or drugs inoculated subcutaneously for 11 days, beginning at time of virus inoculation. * Number of mice paralyzed over total number of mice.
development of viral cytopathic effects in tube cultures under varying concentrations of compound as compared to untreated cultures. In another series of tests reduction of the number and size of plaques with various concentrations of compound in the overlay was measured. Fig. 3 gives a typical example of HBB sensitivity of echo virus 9 recovered on days 7 to 11 after virus inoculation from mice kept either untreated or treated 2 times daily for 91/2 days with 10 mM HBB. No significant difference between virus recovered from mice of either the untreated or HBB group is apparent. Fig. 4 represents corresponding results from guanidine-treated mice. Results of this nature were obtained in large series of experiments using either the tube or plaque reduction method. Similar results were also obtained with HBB-or guanidine-treated mice infected with Coxsackie A 9 virus (see below). Thus, we conclude that development of drug-resistant variants cannot be a significant factor for the failure of treatment when HBB or gnanidine is administered alone. So far, we recorded only one instance when a sample of Coxsackie A 9 virus from a mouse successfully treated with HBB plus guanidine was significantly more resistant to HBB and guanidine, respectively, than the parent virus. This, however, might be an epiphenomenon, since samples from other mice of the same group exhibited an HBB and guanidine sensitivity like that of the virus inoculum.
Treatment of Mice Infected with Drug-resistant Virus.
Though the data presented so far favor the conclusion that the protective effects of treatment are due to the virus-selective activity of the compounds, stronger evidence on this point appeared desirable. We, therefore, tried to prepare an echo virus 9 mutant doubly resistant to HBB and guanidine, respectively. Although it is very easy to isolate drug-resistant mutants in cell culture, these mutants usually are no longer mouse pathogenic. After many futile attempts, we succeeded in obtaining a mutant highly resistant to HBB and guanidine as compared to the parent virus (Fig. 5 ), exhibiting about one PDso when given undiluted (about 106"7 TCIDso per 0.1 ml). With this virus preparation standard growth curves in four litters of mice were performed, two of which were treated 2 times daily with saline, the other two with 10 mM HBB plus 100 mM guanidine. For comparison, drug-sensitive parent virus was used in an experiment of the same design. As can be seen in Fig. 6 , multiplication of drug-sensitive virus was strongly inhibited in the drugtreated group and, as expected, residual drug-treated mice not taken for virus titration remained well in contrast to saline-treated mice. On the other hand, HBB sensitivity of echo virus 9 recovered from m~ce kept untreated or treated with the multiplication of the HBB-guanidine-resistant echo virus 9 mutant was quite similar in both the saline-and the drug-treated group. Clinically, two out of five mice in the saline group, not taken for virus titration, exhibited paresis; in the drug-treated group two out of four remaining mice were paretic. The results of this experiment leave hardly any doubt that the protection of mice treated with HBB and guanidine is due to the specific virus-inhibitory activity of these compounds. Fig. 7) : no apparent virus multiplication until at least day 4 after infection in the HBB-guanidine-treated group, and a significant delay in the HBB-treated group as compared to the saline group, a delay quite sufficient for protection of the animals. In guanidine-treated animals, no inhibition of virus multiplication as compared to controls was demonstrated (figure not shown).
The fact that HBB treatment alone protected Coxsackie A 9-but not echo virus 9-infected mice, could be thought of as being due to a higher HBB sensitivity of the Coxsackie A 9 as compared to the echo virus 9, though in previous studies such a difference has not been noted (8, 17) . Upon careful re-10o examination in simultaneous tests (Fig. 8) , no difference in HBB sensitivity between Coxsackie A 9 and echo virus 9 was detected. We conclude that factors other than HBB sensitivity are responsible for the effectiveness of HBB treatment in Coxsackie A 9 virus-infected mice.
Immunity of Echo Virus 9-infected, HBB-Guanidine-treated Mice. Though immunity of previously infected HBB-guanidine-treated mice for obvious reasons cannot be measured directly in challenge studies, two observations strongly suggest that, in fact, a solid immunity does develop. Firstly, sera taken from a number of echo virus 9-infected, HBB-guanidine-treated mice at the age of about 2 mo, all contained echo virus 9 neutralizing antibodies, though, on the average, in somewhat lower titers than those found in untreated or salinetreated animals. Secondly, children born to and fed by mothers which 2 mo previously had been protected by HBB-guanidine treatment from echo virus 9 disease, were solidly immune to homologous virus infection administered within 24 h after birth, but succumbed to Coxsackie A 9 virus challenge.
Discussion
Combined treatment of echo virus 9-infected, newborn mice with HBB plus guanidine protects them from paralysis and death, even when more than 1,000 PD5o of virus are inoculated. HBB or guanidine alone are ineffective. Treatment 
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Fzo. 6. Multiplication of HBB-guanidine-resistant and d~g-sensitive echo vinzs 9 in mice treated either with saline or HBB-guanidine two times daily for 101/2 days.
was usually begun at the time of virus inoculation and extended through 10 days, but it may be cut short to 3 days of treatment beginning at time of virus inoculation. Treatment may also be delayed for 48 h after virus inoculation and still be effective. Coxsackie A 9 virus-infected mice are not only protected from paralysis and death by combined treatment, but also by treatment with HBB alone. Guanidine alone, however, does not protect.
That success of treatment is due to the well-studied antiviral activities of HBB and guanidine is strongly suggested by the following finding. There exists a good correlation between protective activity of the compounds and inhibition of * 0.02 ml of saline or drugs inoculated subcutaneously two times daily for 10 days, beginning at time of virus inoculation. * Number of mice paralyzed over total number of mice.
virus multiplication in the mice. In particular, HBB-guanidine-resistant mutants prepared in cell culture multiply unaffected in treated mice, and those mice do not respond to treatment.
A most critical factor for success of treatment in echo virus 9-infected mice appears to be a pharmacological one, viz, to reach an adequate concentration of drugs in the target organ, the skeleton muscle. If our standard dose of combined treatment is only halved, either by lowering the concentration of drugs or by reducing the number of injections, still a significant protective effect is achieved, but it is borderline, and quarter doses are ineffective (Tables V and  VI) . On the other hand, due to toxicity the concentration of guanidine can at most be increased by a factor of two.
Considering the above dose-effect relationships and the very strong synergistic effects of HBB plus guanidine (9, 12) , the failure of treatment with either drug alone in the case of echo virus 9 infection appears reasonably explained. Whatever the pharmacological basis, in the broadest sense, may be: at the site of action in the muscle not too effective concentrations of either drug are being reached. More detailed pharmacokinetic studies are under way to shed more light on this point, in particular, whether the conditions in the muscle are comparable to those of cell culture systems.
That the situation may be a more complex one is already suggested by the present study: though in cell culture Coxsackie A 9 virus is not more sensitive to HBB than echo virus 9 (Fig. 8) , its multiplication in the muscle is inhibited by administration to the mouse of 10 mM HBB alone, which latter concentration is also clinically effective, whereas in the case of echo virus 9 even 20 mM HBB is ineffective. It may be speculated that in the mouse muscle the sites of attack of Coxsackie A 9 and echo virus 9, respectively, are not the same. This problem is being investigated at present in our laboratory.
Failure of HBB or guanidine treatment alone, at least in our case, appears not 
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Multiplication of Coxsackie A 9 virus in newborn mice, treated with either saline, HBB plus guanidine, or HBB alone.
to be due to the rapid emergence of drug-resistant virus mutants as anticipated first by analogy with cell culture studies and by the reports that after treatment of poliovirus-infectod monkeys with HBB or guanidine, HBB-or guanidineresistant mutants of poliovirus were readily isolated (4, 7). In extensive series of experiments we were unable to isolate HBB-or guanidine-resistant mutants from treated animals. Thus, failure of treatment with each compound alone appears not to be a result of development of drug-resistant mutants, and the protective activity of combined treatment in all likelihood is a consequence of the synergism between HBB and guanidine, and not that of the limited crossresistance between HBB-or guanidine-resistant variants, respectively. O'Sullivan et al. in a study with the 1-propyl derivative of HBB in Coxsackie A 9 virus-infected mice also found no evidence for formation of resistant virus (5). It
is not yet clear why guanidine-or HBB-resistant mutants of poliovirus are so readily isolated from guanidine-or HBB-treated monkeys.
Hollinshead and Smith (3) were the first to report therapeutic effects of HBB. They fed the free base of HBB in the diet to mice, infected with poliovirus 2 (MEF1), and recorded reduction of death (8/11 Comparative drug sensitivity of Coxsackie A 9 virus and echo virus 9.
treated group). It should be emphasized that poliovirus is relatively HBBinsensitive (8) , and in another series of experiments HBB did not protect poliovirus-infected mice (4). In the above mentioned study with 1-propyl-HBB in Coxsackie A 9 virus-infected mice (5), the authors gave the free base suspended in corn oil intraperitoneally in doses up to 1.6 mg per mouse per day (our standard dose 0.09 mg per mouse per day). With 3 days of treatment (usually 0.8 mg per mouse per day, distributed in two doses), beginning at time of virus inoculation, they achieved a delay in occurrence of death (with 20 LDso of virus) or a slight protection of 46% survival vs. 25% survival in the control (two LD50 of virus). Any possible advantages of the procedures of treatment with the benzimidazole derivatives alone in O'Sullivan's et al. and our study cannot be evaluated properly yet, since the systems may not be comparable. A controlled series of experiments is under way. It should be stated, however, that in cell culture we did not find 1-propyl-HBB superior in its virus selectivity to DL-HBB, the racemic form , unpublished results), not to speak of the D-isomer of HBB.
Combined treatment of Coxsackie B virus-infected mice (types 2 and 4) so far gave only marginal beneficial effects (unpublished). In further experiments, the pharmacology of the substances in the organism will be considered in great detail; at present it appears to us a key problem in the pursuit of our studies. Summary Echo virus 9-or Coxsackie A 9-infected newborn mice are protected from paralysis and death by combined treatment with nontoxic concentrations of HBB plus guanidine. HBB alone also protects Coxsackie A 9, but not echo virus 9-infected animals, whereas guanidine alone is ineffective in either case. Protection is due to inhibition of virus multiplication via the antiviral activity of these selective inhibitors. Treatment must be begun at the latest 48 h after virus inoculation. 3 days of treatment are sufficient if started at the time of virus inoculation. Failure of protection after treatment with one compound alone is not due to rapid development of drug-resistant virus mutants. Infected, successfully treated mice may develop a solid immunity.
